| NCT06701513 | Bristol-Myers Squibb | Psoriasis | 2025-01-29 | |
| NCT05946941 | Bristol-Myers Squibb | Sj?gren´s Syndrome | 2023-09-11 | PHASE3 |
| NCT06042920 | Bristol-Myers Squibb | Palmoplantar Psoriasis|Genital Psoriasis | 2023-10-09 | PHASE4 |
| NCT06532136 | Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb | Papulopustular Rosacea | 2024-11 | PHASE2 |
| NCT05620407 | Bristol-Myers Squibb | Systemic Lupus Erythematosus | 2023-01-12 | PHASE3 |
| NCT05124080 | University of Alabama at Birmingham | Nail Psoriasis | 2024-03-01 | EARLY_PHASE1 |
| NCT07116967 | Bristol-Myers Squibb | Plaque Psoriasis | 2025-09-22 | PHASE3 |
| NCT04908202 | Bristol-Myers Squibb | Psoriatic Arthritis | 2021-07-13 | PHASE3 |
| NCT06869551 | Bristol-Myers Squibb | Juvenile Psoriatic Arthritis | 2025-03-13 | PHASE3 |
| NCT05617677 | Bristol-Myers Squibb | Systemic Lupus Erythematosus | 2023-01-12 | PHASE3 |
| NCT07564271 | Peking University People´s Hospital | Idiopathic Inflammatory Myopathies (IIMs) | 2025-10-05 | |
| NCT05997277 | Beth Israel Deaconess Medical Center|Bristol-Myers Squibb | Hidradenitis Suppurativa | 2023-11-30 | PHASE2 |
| NCT05744466 | Bristol-Myers Squibb | Psoriasis | 2022-09-30 | |
| NCT05858645 | University of California, San Francisco|Bristol-Myers Squibb | Psoriasis Vulgaris | 2023-10-01 | PHASE4 |
| NCT07017699 | Bristol-Myers Squibb | Psoriasis (PsO) | 2025-03-21 | |
| NCT04949269 | Bristol-Myers Squibb | Healthy Participants | 2021-07-20 | PHASE1 |
| NCT07352566 | University of California, San Francisco | Psoriasis|Atopic Dermatitis | 2026-01-01 | PHASE4 |
| NCT05821374 | Dartmouth-Hitchcock Medical Center|Bristol-Myers Squibb | Pyoderma Gangrenosum | 2024-04-29 | EARLY_PHASE1 |
| NCT07508488 | Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb | Central Centrifugal Cicatricial Alopecia|Frontal Fibrosing Alopecia | 2026-04 | PHASE2 |
| NCT04877990 | Bristol-Myers Squibb | Crohn Disease|Ulcerative Colitis | 2021-05-07 | PHASE2 |
| NCT04772079 | Bristol-Myers Squibb | Plaque Psoriasis | 2021-03-23 | PHASE3 |
| NCT06725264 | Yale University|Bristol-Myers Squibb | Sarcoidosis|Granuloma Annulare | 2025-03 | PHASE2 |
| NCT04908189 | Bristol-Myers Squibb | Psoriatic Arthritis | 2021-07-15 | PHASE3 |
| NCT06333860 | AbbVie | Moderate Plaque Psoriasis | 2024-05-10 | PHASE4 |
| NCT04857034 | Bristol-Myers Squibb | Lupus Erythematosus, Discoid|Lupus Erythematosus, Subacute Cutaneous | 2021-07-12 | PHASE2 |
| NCT06327321 | Centre Hospitalier Universitaire de Nice | Vitiligo, Generalized | 2024-05-05 | PHASE2 |
| NCT06979453 | Bristol-Myers Squibb | Plaque Psoriasis | 2025-12-03 | PHASE3 |
| NCT05478499 | Bristol-Myers Squibb | Psoriasis | 2022-10-06 | PHASE4 |
| NCT06851871 | Bristol-Myers Squibb | Healthy Participants | 2025-01-23 | PHASE1 |
| NCT06329258 | Psoriasis Treatment Center of Central New Jersey | Psoriasis | 2022-12-06 | PHASE4 |
| NCT06566768 | Bristol-Myers Squibb | Healthy Participants | 2024-10-07 | PHASE1 |
| NCT07256015 | Bristol-Myers Squibb | Psoriasis | 2025-08-05 | |
| NCT06999941 | Xi Tan | Psoriasis|Eczema|JAK Inhibitor | 2025-04-24 | |
| NCT06258668 | Bristol-Myers Squibb | Moderate-to-severe Plaque Psoriasis | 2024-08-21 | |
| NCT06091956 | Mayo Clinic|Bristol-Myers Squibb | Lichen Planopilaris | 2023-11-07 | PHASE2 |
| NCT05556265 | Bristol-Myers Squibb | Alopecia Areata | 2022-11-08 | PHASE2 |
| NCT06281106 | Prof Curdin Conrad|Centre Hospitalier Universitaire Vaudois | Psoriasis | 2024-06-20 | PHASE2|PHASE3 |
| NCT05701995 | Bristol-Myers Squibb | Psoriasis | 2023-01-31 | PHASE4 |
| NCT05710185 | Brigham and Women´s Hospital|University of Pennsylvania | Palmoplantar Pustulosis | 2023-07-01 | PHASE4 |
| NCT06444399 | Mayo Clinic | Pityriasis Rubra Pilaris | 2024-07-29 | PHASE2 |
| NCT06143878 | Janssen Research & Development, LLC | Plaque Psoriasis | 2024-02-01 | PHASE3 |
| NCT06220604 | Janssen Research & Development, LLC | Plaque Psoriasis | 2024-03-09 | PHASE3 |
| NCT06476834 | Bristol-Myers Squibb | Healthy Volunteers | 2024-06-24 | PHASE4 |
| NCT06136403 | Centre Hospitalier Universitaire de Nice | Epidermolysis Bullosa Simplex|Ichthyosis|Genodermatosis|Inflammatory Congenital Ichthyoses | 2024-03-18 | PHASE2 |
| NCT07000630 | Peking University First Hospital | Palmoplantar Pustulosis | 2025-06-20 | NA |
| NCT06382987 | Bristol-Myers Squibb | Plaque Psoriasis | 2024-01-22 | |
| NCT07013838 | Chinese SLE Treatment And Research Group | Takayasu Arteritis (TAK) | 2025-06-15 | PHASE4 |
| NCT06973291 | Takeda | Plaque Psoriasis | 2025-07-09 | PHASE3 |
| NCT06104644 | Bristol-Myers Squibb | Plaque Psoriasis | 2023-04-13 | |
| NCT06512337 | Bristol-Myers Squibb | Plaque Psoriasis | 2025-01-20 | |
| NCT04209699 | Bristol-Myers Squibb | Healthy Participants | 2019-12-27 | PHASE1 |
| NCT03611751 | Bristol-Myers Squibb | Psoriasis | 2018-07-26 | PHASE3 |
| NCT03890770 | Bristol-Myers Squibb | Renal Impairment|Healthy Volunteer | 2019-04-04 | PHASE1 |
| NCT04113668 | Bristol-Myers Squibb | Healthy Participants | 2019-10-01 | PHASE1 |
| NCT03419910 | Bristol-Myers Squibb | Psoriasis | 2018-03-05 | PHASE1 |
| NCT04065932 | Bristol-Myers Squibb | Lupus | 2019-08-22 | PHASE1 |
| NCT03624127 | Bristol-Myers Squibb | Psoriasis | 2018-08-07 | PHASE3 |
| NCT03252587 | Bristol-Myers Squibb | Systemic Lupus Erythematosus | 2017-09-21 | PHASE2 |
| NCT03751228 | Bristol-Myers Squibb | Healthy Participants | 2018-10-11 | PHASE1 |
| NCT03881059 | Bristol-Myers Squibb | Active Psoriatic Arthritis | 2019-04-01 | PHASE2 |
| NCT03890809 | Bristol-Myers Squibb | Liver Dysfunction|Healthy Volunteers | 2019-02-26 | PHASE1 |
| NCT03934216 | Bristol-Myers Squibb | Ulcerative Colitis | 2019-07-01 | PHASE2 |
| NCT02931838 | Bristol-Myers Squibb | Psoriasis | 2016-11-15 | PHASE2 |
| NCT03541564 | Bristol-Myers Squibb | Systemic Lupus Erythematosus|Healthy Participants | 2018-05-30 | PHASE1 |
| NCT04036435 | Bristol-Myers Squibb | Psoriasis | 2019-08-12 | PHASE3 |
| NCT04536961 | Bristol-Myers Squibb | Healthy Volunteers | 2020-09-10 | PHASE1 |
| NCT06875960 | Bristol-Myers Squibb | Systemic Lupus Erythematosus (SLE)|Discoid and+or Subacute Cutaneous Lupus Erythematosus (DLE+SCLE) | 2026-02-24 | PHASE4 |
| NCT07335796 | Memorial Sloan Kettering Cancer Center | Prostate Cancer | 2026-01-09 | PHASE2 |
| NCT02534636 | Bristol-Myers Squibb | Healthy Subjects | 2015-10 | PHASE1 |
| NCT04249284 | Bristol-Myers Squibb | Healthy Participants | 2020-02-06 | PHASE1 |
| NCT03930602 | Bristol-Myers Squibb | Healthy | 2019-05-01 | PHASE1 |
| NCT04086719 | Bristol-Myers Squibb | Healthy Male Volunteers | 2019-09-12 | PHASE1 |
| NCT03920267 | Bristol-Myers Squibb | Systemic Lupus Erythematosus | 2019-03-26 | PHASE2 |
| NCT03924427 | Bristol-Myers Squibb | Psoriasis | 2019-04-10 | PHASE3 |
| NCT03739788 | Bristol-Myers Squibb | Healthy Participants | 2018-12-05 | PHASE1 |
| NCT03262727 | Bristol-Myers Squibb | Systemic Lupus Erythematosus|Arthritic Psoriasis|Psoriasis|Inflammatory Bowel Diseases | 2017-09-01 | PHASE1 |
| NCT07326813 | InventisBio Co., Ltd | Plaque Psoriasis | 2026-01-12 | PHASE3 |
| NCT04167462 | Bristol-Myers Squibb | Psoriasis | 2019-11-25 | PHASE3 |
| NCT03044873 | Bristol-Myers Squibb | Autoimmune Diseases|Inflammatory Diseases | 2017-02-02 | PHASE1 |
| NCT03943147 | Bristol-Myers Squibb | Lupus Nephritis | 2019-07-15 | PHASE2 |
| NCT03873415 | Bristol-Myers Squibb | Psoriasis | 2019-01-25 | PHASE1 |
| NCT04613518 | Bristol-Myers Squibb | Colitis, Ulcerative | 2021-03-15 | PHASE2 |
| NCT04305899 | Bristol-Myers Squibb | Healthy Participants | 2020-08-31 | PHASE1 |
| NCT04671953 | Bristol-Myers Squibb | Healthy Participants | 2020-12-18 | PHASE1 |
| NCT03004768 | Bristol-Myers Squibb|Covance | Psoriasis | 2017-01-26 | PHASE1 |
| NCT03254784 | Bristol-Myers Squibb | Systemic Lupus Erythematosus|Arthritic Psoriasis|Psoriasis|Inflammatory Bowel Diseases | 2017-09-13 | PHASE1 |
| NCT03979248 | Bristol-Myers Squibb | Healthy | 2019-05-16 | PHASE1 |
| NCT03402087 | Bristol-Myers Squibb | Lupus|Psoriatic Arthritis | 2018-01-08 | PHASE1 |
| NCT03599622 | Bristol-Myers Squibb | Granulomatous Colitis|Crohn´s Disease|Crohn´s Enteritis|Granulomatous Enteritis | 2018-07-16 | PHASE2 |
| NCT03956953 | Bristol-Myers Squibb | Autoimmune Diseases | 2019-04-04 | PHASE1 |
| NCT03660436 | Bristol-Myers Squibb | Healthy Participants | 2018-08-14 | PHASE1 |
| NCT04055506 | Bristol-Myers Squibb | Healthy Participants | 2019-08-14 | PHASE1 |